

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 May 2023 (04.05.2023)



(10) International Publication Number
WO 2023/077094 A1

(51) International Patent Classification:

A61K 31/495 (2006.01) C07D 295/033 (2006.01)
A61P 25/24 (2006.01) A61P 25/00 (2006.01)

(21) International Application Number:

PCT/US2022/078922

(22) International Filing Date:

28 October 2022 (28.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/263,213 28 October 2021 (28.10.2021) US
63/362,446 04 April 2022 (04.04.2022) US

(71) Applicants: **ABBVIE INC.** [US/US]; 1 N. Waukegan Road, AP34-2 V377, North Chicago, IL 60064 (US). **ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED** [IE/IE]; Clonsaugh Business & Technology Park, D17 E400 (IE).

(72) Inventors; and


(71) Applicants: **REKEDA, Ludmyla**; 206 Hudson Street, Hoboken, NJ 07030 (US). **BUDÜR, Kumar**; 701 S Wells Street # 2103, Chicago, IL 60607 (US). **EARLEY, Willie**; 1002 Radley Drive, West Chester, NJ 19382 (US).

(74) Agent: **JOHANNES, Laura** et al.; c/o AbbVie Inc., AP34-2 V0377, 1 North Waukegan Road, North Chicago, IL 60064 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: TREATMENT OF MAJOR DEPRESSIVE DISORDER

Figure 1. Study Schematic



(57) Abstract: The present disclosure provides methods for the treatment of major depressive disorder (MDD) by administering cariprazine or a pharmaceutically acceptable salt thereof, as an adjunct to antidepressant therapy in the treatment of subjects with major depressive disorder. The administration of cariprazine achieves statistically significant change from baseline to Week 6 in the Montgomery Asberg Depression Rating Scale (MADRS) total score.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))